Loading…
Employees: 34,848
Size Yixintang Pharmaceutical (002727.SZ) is a China Consumer Staples company (Drugstore Chains) with a market value of $1.18B, the 2002nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.48 on 6 Nov 2026.
Performance Over six months the shares gained 6.3%, against -2.0% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 19 in its peer set.
Growth Revenue fell 2.0% over the last twelve months (peer median +7.7%); the operating margin is 3.3% (peer median 4.7%).
Valuation It trades at 16.9× forward earnings against a peer median of 16.3× (4th most expensive of 12).
Price implies For today's price to make sense, revenue must grow about -16% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -22 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.6 points above its cost of capital (5.8% WACC).
Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥17.0B | CN¥17.3B | CN¥17.9B | CN¥17.3B | CN¥17.4B |
| Revenue growth | — | -3% | +4% | 0% | — |
| Gross profit | CN¥6.56B | CN¥5.52B | CN¥5.54B | CN¥5.57B | CN¥6.00B |
| EBITDA | n/a | CN¥1.95B | CN¥1.82B | CN¥2.17B | CN¥2.47B |
| Net income | CN¥376M | CN¥263M | CN¥114M | CN¥549M | CN¥1.01B |
| Free cash flow | CN¥1.85B | CN¥1.37B | CN¥1.49B | CN¥1.86B | CN¥2.16B |
| Capital expenditure | CN¥298M | CN¥278M | CN¥255M | CN¥253M | CN¥349M |
| Total debt | CN¥3.86B | CN¥4.86B | CN¥5.30B | CN¥4.89B | CN¥4.81B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002727.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +25.4% | +0.8% | highest of 19 |
| 6-month return | +6.3% | -2.0% | 7th highest of 19 |
| Distance from 52-week high | -8.9% | -33.2% | 4th highest of 19 |
| Revenue growth (TTM) | -2.0% | +7.7% | 2nd lowest of 19 |
| Operating margin | 3.3% | 4.7% | 7th lowest of 19 |
| Forward P/E | 16.9× | 16.3× | 4th most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | -15.9% | -6.3% | 2nd least demanding of 17 |
| Growth delivered (Del g) | +6.5% | +11.7% | 6th lowest of 17 |
| Hurdle (Req g minus delivered) | -22.4 pp | -16.7 pp | 6th least demanding of 17 |
| ROIC minus cost of capital | +8.6 pp | +2.7 pp | 4th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Yixintang Pharmaceutical 002727.SZ | China | $1.18B | +6% | -2% | 3% | 16.9× | -15.9% | +6.5% |
| Ain 9627.T | Japan | $1.23B | -2% | +42% | 4% | 13.4× | -6.5% | +16.9% |
| Create SD 3148.T | Japan | $1.30B | -2% | +9% | 5% | n/a | -11.5% | +8.0% |
| Shu Yu Civilian Pharmacy 301017.SZ | China | $872M | +9% | +9% | 2% | n/a | 4.0% | +17.4% |
| Anhui Huaren Health Pharmaceutical 301408.SZ | China | $829M | -35% | +15% | 8% | n/a | -6.0% | +23.3% |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.69B | +7% | +3% | 5% | 16.3× | -10.9% | +9.7% |
| MedPlus Health Services MEDPLUS.NS | India | $769M | -31% | +21% | 4% | 35.1× | 18.5% | +17.6% |
| Genky DrugStores 9267.T | Japan | $723M | +3% | +8% | 5% | 13.7× | n/a | n/a |
| Beijing Konruns Pharmaceutical 603590.SS | China | $617M | -28% | +4% | 20% | 21.0× | 11.6% | +2.7% |
| Cawachi 2664.T | Japan | $577M | +37% | -1% | 2% | n/a | -5.8% | 0.0% |
| Qol 3034.T | Japan | $567M | +38% | +7% | 6% | 11.3× | -16.2% | +12.4% |
| Luyan Pharma 002788.SZ | China | $555M | -30% | +3% | 3% | n/a | 0.1% | +6.5% |
| Guardian Pharmacy Services GRDN | United States | $2.68B | +17% | +10% | 6% | 30.6× | 4.1% | +16.8% |
| Sundrug 9989.T | Japan | $2.77B | -1% | +4% | 5% | 13.3× | -8.0% | +5.8% |
| Sugi 7649.T | Japan | $3.27B | -23% | +9% | 5% | 16.8× | -9.7% | +10.9% |
| Landfar Bio-medicine 000504.SZ | China | $395M | -16% | +497% | -2% | n/a | n/a | n/a |
| DaShenLin Pharmaceutical 603233.SS | China | $3.80B | +15% | +7% | 8% | 16.6× | -9.0% | +13.6% |
| Shanghai No. 1 Pharmacy 600833.SS | China | $314M | -24% | +1% | -1% | n/a | 20.4% | +6.1% |
| JZJ Chain Drugstore Corporation 605266.SS | China | $307M | -34% | -5% | 0% | 6.5× | -9.6% | +14.8% |